SeekingAlpha · Oct 21, 2026
Omeros: The Trade After European Rejection
Omeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this indication. See why I rate OMER stock a hold.
OM
NASDAQ · OMER
Omeros Corporation
Healthcare · Biotechnology
$18.44
Down-$0.51 (-2.69%)
Updated Nov 2, 2026, 11:48 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 750.41M
- P/E ratio
- -5.79
- Dividend yield
- 0.00%
- 52-week range
- $6.70 – $21.24
- Volume
- 885.58K
- Avg. volume
- 3.6M
Price performance · OMER
OMER price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OMER closed at $18.44 after 20 trading sessions, down 2.43% for the selected period.
- Last close
- $18.44
- Period change
- -2.43%
- Period low
- $16.20
- Period high
- $19.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $18.53 | $19.0065 | $18.045 | $18.44 | 885.58K |
| Oct 29, 2026 | $17.97 | $19.28 | $17.69 | $18.95 | 3.63M |
| Oct 28, 2026 | $17.37 | $17.90 | $17.25 | $17.88 | 604.49K |
| Oct 27, 2026 | $16.30 | $17.51 | $16.20 | $17.49 | 895.06K |
| Oct 26, 2026 | $16.78 | $16.78 | $16.21 | $16.29 | 741.39K |
| Oct 23, 2026 | $16.80 | $16.80 | $16.37 | $16.57 | 699.39K |
| Oct 22, 2026 | $16.26 | $16.885 | $16.15 | $16.86 | 737.28K |
| Oct 21, 2026 | $16.57 | $16.665 | $16.205 | $16.26 | 698.21K |
| Oct 20, 2026 | $16.42 | $16.78 | $16.11 | $16.55 | 725.47K |
| Oct 19, 2026 | $16.28 | $16.65 | $16.045 | $16.35 | 1.38M |
| Oct 16, 2026 | $17.94 | $17.94 | $15.845 | $16.20 | 3.97M |
| Oct 15, 2026 | $18.50 | $19.0755 | $18.30 | $18.79 | 931.37K |
| Oct 14, 2026 | $18.58 | $19.27 | $18.39 | $18.43 | 905.11K |
| Oct 13, 2026 | $19.50 | $19.78 | $18.83 | $18.88 | 994.06K |
| Oct 12, 2026 | $19.735 | $20.24 | $19.47 | $19.63 | 1.07M |
| Oct 9, 2026 | $19.20 | $19.905 | $19.19 | $19.83 | 793.93K |
| Oct 8, 2026 | $18.63 | $19.14 | $18.41 | $19.12 | 899.92K |
| Oct 7, 2026 | $18.11 | $18.84 | $18.02 | $18.75 | 622.92K |
| Oct 6, 2026 | $18.95 | $18.99 | $18.31 | $18.51 | 1.03M |
| Oct 5, 2026 | $18.82 | $19.15 | $18.55 | $18.90 | 1.07M |
Latest OMER news
The latest Smart Investors Daily articles mentioning OMER.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OMER research
Overview
Company profile and research snapshot.
Company profile
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 22, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 26, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 16, 2026
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.1% and the
Yahoo · Oct 16, 2026
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday.
Yahoo · Oct 16, 2026
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros Corporation (NASDAQ:OMER) shares declined 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the company’s marketing authorisation application for narsoplimab. The decision followed a formal re-examination of the application for narsoplimab as a treatment for haematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious complication that can develo
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
